ReviewAnnals of medicine2026
Subacromial bursitis: current evidence and future directions in injection-based therapies-A narrative review.
Review in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo review the anatomical and physiological characteristics of subacromial bursitis (SAB), clarify its pathogenesis and commonly used imaging diagnostic methods, and summarize the clinical efficacy, current application status, and future research directions of various injectable agents for SAB.
methodsThis narrative review performed a non-systematic literature search in PubMed and Web of Science for injection therapies for SAB and related conditions , focusing on clinical trials and systematic reviews.
resultsCorticosteroids (CS) remain the most widely used, providing robust short-term pain relief but with potential long-term complications. Randomized controlled trials suggest hyaluronic acid, nonsteroidal anti-inflammatory drugs, and hypertonic glucose offer alternative or adjunctive options. Emerging biologics like platelet-rich plasma (PRP) and interleukin-1 antagonists show promise but low-quality evidence. Ultrasound guidance enhances injection precision, and combining injection with physical rehabilitation optimizes outcomes.
conclusionThe choice of injectable agent requires balancing CS's rapid effects against safer but less established alternatives. Future research should validate PRP, HA, IL-1Ra, and hypertonic glucose via large RCTs, develop combination strategies (e.g., CS+HA), integrate advanced ultrasound techniques (e.g., hydrodissection), and identify patient-specific factors (e.g., inflammatory endotypes, concomitant rotator cuff pathology) for personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.